Global and United States Bi-Specific Antibodies Therapy Market Report & Forecast 2022-2028

• Description
• Table of Contents
• Table of Figures
• PDF Download

• Description
• Table of Contents
• Table of Figures
• PDF Download

A bispecific antibody (BsAb), or specific monoclonal antibody (BsMAb) is an artificial protein comprised of fragments from two different antibodies. By virtue of the inclusion of two different antigen binding regions, a bispecific antibody is capable of recognizing and binding to two different antigens, or two different epitope on an antigen.

Market Analysis and Insights: Global and United States Bi-Specific Antibodies Therapy Market
This report focuses on global and United States Bi-Specific Antibodies Therapy market, also covers the segmentation data of other regions in regional level and county level.

Due to the COVID-19 pandemic, the global Bi-Specific Antibodies Therapy market size is estimated to be worth US$ 4201.5 million in 2022 and is forecast to a readjusted size of US$ 17140 million by 2028 with a CAGR of 26.4% during the review period. Fully considering the economic change by this health crisis, by Type, Fragment-Based Antibodies accounting for % of the Bi-Specific Antibodies Therapy global market in 2021, is projected to value US$  million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While by Application, Cancer was the leading segment, accounting for over  percent market share in 2021, and altered to an  % CAGR throughout this forecast period.

Global Bi-Specific Antibodies Therapy key players include Roche, Amgen, Sanofi, Pfizer, Johnson & Johnson, etc. Global top five manufacturers hold a share over 95%.

North America is the largest market, with a share about 65%, followed by Europe and China, both have a share over 30 percent. In terms of product, IgG-Based Antibodies is the largest segment, with a share over 85%. And in terms of application, the largest application is Haemophilia, followed by Cancer, etc.

Global Bi-Specific Antibodies Therapy Scope and Market Size
Bi-Specific Antibodies Therapy market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Bi-Specific Antibodies Therapy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.

For United States market, this report focuses on the Bi-Specific Antibodies Therapy market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.

Segment by Type, the Bi-Specific Antibodies Therapy market is segmented into
    Fragment-Based Antibodies
    IgG-Based Antibodies

Segment by Application, the Bi-Specific Antibodies Therapy market is segmented into
    Cancer
    Haemophilia
    Other Non-Cancer Diseases

Regional and Country-level Analysis
    North America
        United States
        Canada
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
    Asia-Pacific
        China
        Japan
        South Korea
        India
        Australia
        China Taiwan
        Indonesia
        Thailand
        Malaysia
    Latin America
        Mexico
        Brazil
        Argentina
    Middle East & Africa
        Turkey
        Saudi Arabia
        UAE

Competitive Landscape and Bi-Specific Antibodies Therapy Market Share Analysis
Bi-Specific Antibodies Therapy market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2017-2022. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2017-2022. Details included are company description, major business, company total revenue and the sales, revenue generated in Bi-Specific Antibodies Therapy business, the date to enter into the Bi-Specific Antibodies Therapy market, Revenue in Bi-Specific Antibodies Therapy Business (2017-2022) & (US$ Million) introduction, recent developments, etc.

The major vendors covered:
    Roche
    Amgen
    Sanofi
    Pfizer
    Johnson & Johnson
    AstraZeneca
    AbbVie
    Lindis Biotech
    MacroGenics, Inc
    Genmab
    Alphamab Co. Ltd
    Akeso, Inc.

 1 Study Coverage
    1.1 Bi-Specific Antibodies Therapy Revenue in Bi-Specific Antibodies Therapy Business (2017-2022) & (US$ Million) Introduction
    1.2 Global Bi-Specific Antibodies Therapy Outlook 2017 VS 2022 VS 2028
        1.2.1 Global Bi-Specific Antibodies Therapy Market Size for the Year 2017-2028
        1.2.2 Global Bi-Specific Antibodies Therapy Market Size for the Year 2017-2028
    1.3 Bi-Specific Antibodies Therapy Market Size, United States VS Global, 2017 VS 2022 VS 2028
        1.3.1 The Market Share of United States Bi-Specific Antibodies Therapy in Global, 2017 VS 2022 VS 2028
        1.3.2 The Growth Rate of Bi-Specific Antibodies Therapy Market Size, United States VS Global, 2017 VS 2022 VS 2028
    1.4 Bi-Specific Antibodies Therapy Market Dynamics
        1.4.1 Bi-Specific Antibodies Therapy Industry Trends
        1.4.2 Bi-Specific Antibodies Therapy Market Drivers
        1.4.3 Bi-Specific Antibodies Therapy Market Challenges
        1.4.4 Bi-Specific Antibodies Therapy Market Restraints
    1.5 Study Objectives
    1.6 Years Considered

 2 Bi-Specific Antibodies Therapy by Type
    2.1 Bi-Specific Antibodies Therapy Market Segment by Type
        2.1.1 Fragment-Based Antibodies
        2.1.2 IgG-Based Antibodies
    2.2 Global Bi-Specific Antibodies Therapy Market Size by Type (2017, 2022 & 2028)
    2.3 Global Bi-Specific Antibodies Therapy Market Size by Type (2017-2028)
    2.4 United States Bi-Specific Antibodies Therapy Market Size by Type (2017, 2022 & 2028)
    2.5 United States Bi-Specific Antibodies Therapy Market Size by Type (2017-2028)

 3 Bi-Specific Antibodies Therapy by Application
    3.1 Bi-Specific Antibodies Therapy Market Segment by Application
        3.1.1 Cancer
        3.1.2 Haemophilia
        3.1.3 Other Non-Cancer Diseases
    3.2 Global Bi-Specific Antibodies Therapy Market Size by Application (2017, 2022 & 2028)
    3.3 Global Bi-Specific Antibodies Therapy Market Size by Application (2017-2028)
    3.4 United States Bi-Specific Antibodies Therapy Market Size by Application (2017, 2022 & 2028)
    3.5 United States Bi-Specific Antibodies Therapy Market Size by Application (2017-2028)

 4 Global Bi-Specific Antibodies Therapy Competitor Landscape by Company
    4.1 Global Bi-Specific Antibodies Therapy Market Size by Company
        4.1.1 Top Global Bi-Specific Antibodies Therapy Companies Ranked by Revenue (2021)
        4.1.2 Global Bi-Specific Antibodies Therapy Revenue by Player (2017-2022)
    4.2 Global Bi-Specific Antibodies Therapy Concentration Ratio (CR)
        4.2.1 Bi-Specific Antibodies Therapy Market Concentration Ratio (CR) (2017-2022)
        4.2.2 Global Top 5 and Top 10 Largest Companies of Bi-Specific Antibodies Therapy in 2021
        4.2.3 Global Bi-Specific Antibodies Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    4.3 Global Bi-Specific Antibodies Therapy Headquarters, Revenue in Bi-Specific Antibodies Therapy Business (2017-2022) & (US$ Million) Type
        4.3.1 Global Bi-Specific Antibodies Therapy Headquarters and Area Served
        4.3.2 Global Bi-Specific Antibodies Therapy Companies Revenue in Bi-Specific Antibodies Therapy Business (2017-2022) & (US$ Million) Type
        4.3.3 Date of International Companies Enter into Bi-Specific Antibodies Therapy Market
    4.4 Companies Mergers & Acquisitions, Expansion Plans
    4.5 United States Bi-Specific Antibodies Therapy Market Size by Company
        4.5.1 Top Bi-Specific Antibodies Therapy Players in United States, Ranked by Revenue (2021)
        4.5.2 United States Bi-Specific Antibodies Therapy Revenue by Players (2020, 2021 & 2022)

 5 Global Bi-Specific Antibodies Therapy Market Size by Region
    5.1 Global Bi-Specific Antibodies Therapy Market Size by Region: 2017 VS 2022 VS 2028
    5.2 Global Bi-Specific Antibodies Therapy Market Size by Region (2017-2028)
        5.2.1 Global Bi-Specific Antibodies Therapy Market Size by Region: 2017-2022
        5.2.2 Global Bi-Specific Antibodies Therapy Market Size by Region (2023-2028)

 6 Segment in Region Level & Country Level
    6.1 North America
        6.1.1 North America Bi-Specific Antibodies Therapy Market Size YoY Growth 2017-2028
        6.1.2 North America Bi-Specific Antibodies Therapy Market Facts & Figures by Country (2017, 2022 & 2028)
        6.1.3 United States
        6.1.4 Canada
    6.2 Asia-Pacific
        6.2.1 Asia-Pacific Bi-Specific Antibodies Therapy Market Size YoY Growth 2017-2028
        6.2.2 Asia-Pacific Bi-Specific Antibodies Therapy Market Facts & Figures by Region (2017, 2022 & 2028)
        6.2.3 China
        6.2.4 Japan
        6.2.5 South Korea
        6.2.6 India
        6.2.7 Australia
        6.2.8 China Taiwan
        6.2.9 Indonesia
        6.2.10 Thailand
        6.2.11 Malaysia
    6.3 Europe
        6.3.1 Europe Bi-Specific Antibodies Therapy Market Size YoY Growth 2017-2028
        6.3.2 Europe Bi-Specific Antibodies Therapy Market Facts & Figures by Country (2017, 2022 & 2028)
        6.3.3 Germany
        6.3.4 France
        6.3.5 U.K.
        6.3.6 Italy
        6.3.7 Russia
    6.4 Latin America
        6.4.1 Latin America Bi-Specific Antibodies Therapy Market Size YoY Growth 2017-2028
        6.4.2 Latin America Bi-Specific Antibodies Therapy Market Facts & Figures by Country (2017, 2022 & 2028)
        6.4.3 Mexico
        6.4.4 Brazil
        6.4.5 Argentina
    6.5 Middle East and Africa
        6.5.1 Middle East and Africa Bi-Specific Antibodies Therapy Market Size YoY Growth 2017-2028
        6.5.2 Middle East and Africa Bi-Specific Antibodies Therapy Market Facts & Figures by Country (2017, 2022 & 2028)
        6.5.3 Turkey
        6.5.4 Saudi Arabia
        6.5.5 UAE

 7 Company Profiles
    7.1 Roche
        7.1.1 Roche Company Details
        7.1.2 Roche Business Overview
        7.1.3 Roche Bi-Specific Antibodies Therapy Introduction
        7.1.4 Roche Revenue in Bi-Specific Antibodies Therapy Business (2017-2022)
        7.1.5 Roche Recent Development
    7.2 Amgen
        7.2.1 Amgen Company Details
        7.2.2 Amgen Business Overview
        7.2.3 Amgen Bi-Specific Antibodies Therapy Introduction
        7.2.4 Amgen Revenue in Bi-Specific Antibodies Therapy Business (2017-2022)
        7.2.5 Amgen Recent Development
    7.3 Sanofi
        7.3.1 Sanofi Company Details
        7.3.2 Sanofi Business Overview
        7.3.3 Sanofi Bi-Specific Antibodies Therapy Introduction
        7.3.4 Sanofi Revenue in Bi-Specific Antibodies Therapy Business (2017-2022)
        7.3.5 Sanofi Recent Development
    7.4 Pfizer
        7.4.1 Pfizer Company Details
        7.4.2 Pfizer Business Overview
        7.4.3 Pfizer Bi-Specific Antibodies Therapy Introduction
        7.4.4 Pfizer Revenue in Bi-Specific Antibodies Therapy Business (2017-2022)
        7.4.5 Pfizer Recent Development
    7.5 Johnson & Johnson
        7.5.1 Johnson & Johnson Company Details
        7.5.2 Johnson & Johnson Business Overview
        7.5.3 Johnson & Johnson Bi-Specific Antibodies Therapy Introduction
        7.5.4 Johnson & Johnson Revenue in Bi-Specific Antibodies Therapy Business (2017-2022)
        7.5.5 Johnson & Johnson Recent Development
    7.6 AstraZeneca
        7.6.1 AstraZeneca Company Details
        7.6.2 AstraZeneca Business Overview
        7.6.3 AstraZeneca Bi-Specific Antibodies Therapy Introduction
        7.6.4 AstraZeneca Revenue in Bi-Specific Antibodies Therapy Business (2017-2022)
        7.6.5 AstraZeneca Recent Development
    7.7 AbbVie
        7.7.1 AbbVie Company Details
        7.7.2 AbbVie Business Overview
        7.7.3 AbbVie Bi-Specific Antibodies Therapy Introduction
        7.7.4 AbbVie Revenue in Bi-Specific Antibodies Therapy Business (2017-2022)
        7.7.5 AbbVie Recent Development
    7.8 Lindis Biotech
        7.8.1 Lindis Biotech Company Details
        7.8.2 Lindis Biotech Business Overview
        7.8.3 Lindis Biotech Bi-Specific Antibodies Therapy Introduction
        7.8.4 Lindis Biotech Revenue in Bi-Specific Antibodies Therapy Business (2017-2022)
        7.8.5 Lindis Biotech Recent Development
    7.9 MacroGenics, Inc
        7.9.1 MacroGenics, Inc Company Details
        7.9.2 MacroGenics, Inc Business Overview
        7.9.3 MacroGenics, Inc Bi-Specific Antibodies Therapy Introduction
        7.9.4 MacroGenics, Inc Revenue in Bi-Specific Antibodies Therapy Business (2017-2022)
        7.9.5 MacroGenics, Inc Recent Development
    7.10 Genmab
        7.10.1 Genmab Company Details
        7.10.2 Genmab Business Overview
        7.10.3 Genmab Bi-Specific Antibodies Therapy Introduction
        7.10.4 Genmab Revenue in Bi-Specific Antibodies Therapy Business (2017-2022)
        7.10.5 Genmab Recent Development
    7.11 Alphamab Co. Ltd
        7.11.1 Alphamab Co. Ltd Company Details
        7.11.2 Alphamab Co. Ltd Business Overview
        7.11.3 Alphamab Co. Ltd Bi-Specific Antibodies Therapy Introduction
        7.11.4 Alphamab Co. Ltd Revenue in Bi-Specific Antibodies Therapy Business (2017-2022)
        7.11.5 Alphamab Co. Ltd Recent Development
    7.12 Akeso, Inc.
        7.12.1 Akeso, Inc. Company Details
        7.12.2 Akeso, Inc. Business Overview
        7.12.3 Akeso, Inc. Bi-Specific Antibodies Therapy Introduction
        7.12.4 Akeso, Inc. Revenue in Bi-Specific Antibodies Therapy Business (2017-2022)
        7.12.5 Akeso, Inc. Recent Development

 8 Research Findings and Conclusion

 9 Appendix
    9.1 Research Methodology
        9.1.1 Methodology/Research Approach
        9.1.2 Data Source
    9.2 Author Details
    9.3 Disclaimer

List of Tables
    Table 1. Bi-Specific Antibodies Therapy Market Size United States VS Global, CAGR (2017 VS 2022 VS 2028)
    Table 2. Bi-Specific Antibodies Therapy Market Trends
    Table 3. Bi-Specific Antibodies Therapy Market Drivers
    Table 4. Bi-Specific Antibodies Therapy Market Challenges
    Table 5. Bi-Specific Antibodies Therapy Market Restraints
    Table 6. Global Bi-Specific Antibodies Therapy Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 7. United States Bi-Specific Antibodies Therapy Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 8. Global Bi-Specific Antibodies Therapy Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 9. United States Bi-Specific Antibodies Therapy Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 10. Top Bi-Specific Antibodies Therapy Companies in Global Market, Ranking by Revenue (2021)
    Table 11. Global Bi-Specific Antibodies Therapy Revenue by Player, (US$ Million), 2017-2022
    Table 12. Global Bi-Specific Antibodies Therapy Revenue Share by Player, 2017-2022
    Table 13. Global Bi-Specific Antibodies Therapy Companies Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Bi-Specific Antibodies Therapy by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Bi-Specific Antibodies Therapy as of 2021)
    Table 15. Top Players of Bi-Specific Antibodies Therapy in Global Market, Headquarters and Area Served
    Table 16. Companies Revenue in Bi-Specific Antibodies Therapy Business (2017-2022) & (US$ Million) Type
    Table 17. Date of International Companies Enter into Bi-Specific Antibodies Therapy Market
    Table 18. Companies Mergers & Acquisitions, Expansion Plans
    Table 19. Top Bi-Specific Antibodies Therapy Players in United States Market, Ranking by Revenue (2021)
    Table 20. United States Bi-Specific Antibodies Therapy Revenue by Players, (US$ Million), 2020, 2021 & 2022
    Table 21. United States Bi-Specific Antibodies Therapy Revenue Share by Players, 2020, 2021 & 2022
    Table 22. Global Bi-Specific Antibodies Therapy Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
    Table 23. Global Bi-Specific Antibodies Therapy Market Size by Region (2017-2022) & (US$ Million)
    Table 24. Global Bi-Specific Antibodies Therapy Market Size Forecast by Region (2023-2028) & (US$ Million)
    Table 25. North America Bi-Specific Antibodies Therapy Sales in Value by Country (2017-2028) & (US$ Million)
    Table 26. Asia Pacific Bi-Specific Antibodies Therapy Sales in Value by Region (2017-2028) & (US$ Million)
    Table 27. Europe Bi-Specific Antibodies Therapy Sales in Value by Country (2017-2028) & (US$ Million)
    Table 28. Latin Americaa Bi-Specific Antibodies Therapy Sales in Value by Country (2017-2028) & (US$ Million)
    Table 29. Middle East and Africa Bi-Specific Antibodies Therapy Sales in Value by Country (2017-2028) & (US$ Million)
    Table 30. Roche Company Details
    Table 31. Roche Business Overview
    Table 32. Roche Bi-Specific Antibodies Therapy Product
    Table 33. Roche Revenue in Bi-Specific Antibodies Therapy Business (2017-2022) & (US$ Million)
    Table 34. Roche Recent Development
    Table 35. Amgen Company Details
    Table 36. Amgen Business Overview
    Table 37. Amgen Bi-Specific Antibodies Therapy Product
    Table 38. Amgen Revenue in Bi-Specific Antibodies Therapy Business (2017-2022) & (US$ Million)
    Table 39. Amgen Recent Development
    Table 40. Sanofi Company Details
    Table 41. Sanofi Business Overview
    Table 42. Sanofi Bi-Specific Antibodies Therapy Product
    Table 43. Sanofi Revenue in Bi-Specific Antibodies Therapy Business (2017-2022) & (US$ Million)
    Table 44. Sanofi Recent Development
    Table 45. Pfizer Company Details
    Table 46. Pfizer Business Overview
    Table 47. Pfizer Bi-Specific Antibodies Therapy Product
    Table 48. Pfizer Revenue in Bi-Specific Antibodies Therapy Business (2017-2022) & (US$ Million)
    Table 49. Pfizer Recent Development
    Table 50. Johnson & Johnson Company Details
    Table 51. Johnson & Johnson Business Overview
    Table 52. Johnson & Johnson Bi-Specific Antibodies Therapy Product
    Table 53. Johnson & Johnson Revenue in Bi-Specific Antibodies Therapy Business (2017-2022) & (US$ Million)
    Table 54. Johnson & Johnson Recent Development
    Table 55. AstraZeneca Company Details
    Table 56. AstraZeneca Business Overview
    Table 57. AstraZeneca Bi-Specific Antibodies Therapy Product
    Table 58. AstraZeneca Revenue in Bi-Specific Antibodies Therapy Business (2017-2022) & (US$ Million)
    Table 59. AstraZeneca Recent Development
    Table 60. AbbVie Company Details
    Table 61. AbbVie Business Overview
    Table 62. AbbVie Bi-Specific Antibodies Therapy Product
    Table 63. AbbVie Revenue in Bi-Specific Antibodies Therapy Business (2017-2022) & (US$ Million)
    Table 64. AbbVie Recent Development
    Table 65. Lindis Biotech Company Details
    Table 66. Lindis Biotech Business Overview
    Table 67. Lindis Biotech Bi-Specific Antibodies Therapy Product
    Table 68. Lindis Biotech Revenue in Bi-Specific Antibodies Therapy Business (2017-2022) & (US$ Million)
    Table 69. Lindis Biotech Recent Development
    Table 70. MacroGenics, Inc Company Details
    Table 71. MacroGenics, Inc Business Overview
    Table 72. MacroGenics, Inc Bi-Specific Antibodies Therapy Product
    Table 73. MacroGenics, Inc Revenue in Bi-Specific Antibodies Therapy Business (2017-2022) & (US$ Million)
    Table 74. MacroGenics, Inc Recent Development
    Table 75. Genmab Company Details
    Table 76. Genmab Business Overview
    Table 77. Genmab Bi-Specific Antibodies Therapy Product
    Table 78. Genmab Revenue in Bi-Specific Antibodies Therapy Business (2017-2022) & (US$ Million)
    Table 79. Genmab Recent Development
    Table 80. Alphamab Co. Ltd Company Details
    Table 81. Alphamab Co. Ltd Business Overview
    Table 82. Alphamab Co. Ltd Bi-Specific Antibodies Therapy Product
    Table 83. Alphamab Co. Ltd Revenue in Bi-Specific Antibodies Therapy Business (2017-2022) & (US$ Million)
    Table 84. Alphamab Co. Ltd Recent Development
    Table 85. Akeso, Inc. Company Details
    Table 86. Akeso, Inc. Business Overview
    Table 87. Akeso, Inc. Bi-Specific Antibodies Therapy Product
    Table 88. Akeso, Inc. Revenue in Bi-Specific Antibodies Therapy Business (2017-2022) & (US$ Million)
    Table 89. Akeso, Inc. Recent Development
    Table 90. Research Programs/Design for This Report
    Table 91. Key Data Information from Secondary Sources
    Table 92. Key Data Information from Primary Sources
List of Figures
    Figure 1. Bi-Specific Antibodies Therapy Product Picture
    Figure 2. Global Bi-Specific Antibodies Therapy Market Size, (US$ Million), 2017 VS 2022 VS 2028
    Figure 3. Global Bi-Specific Antibodies Therapy Market Size 2017-2028 (US$ Million)
    Figure 4. United States Bi-Specific Antibodies Therapy Market Size, (US$ Million), 2017 VS 2022 VS 2028
    Figure 5. United States Bi-Specific Antibodies Therapy Market Size 2017-2028 (US$ Million)
    Figure 6. United States Bi-Specific Antibodies Therapy Market Share in Global 2017-2028
    Figure 7. Bi-Specific Antibodies Therapy Report Years Considered
    Figure 8. Product Picture of Fragment-Based Antibodies
    Figure 9. Product Picture of IgG-Based Antibodies
    Figure 10. Global Bi-Specific Antibodies Therapy Market Share by Type in 2022 & 2028
    Figure 11. Global Bi-Specific Antibodies Therapy Market Size by Type (2017-2028) & (US$ Million)
    Figure 12. Global Bi-Specific Antibodies Therapy Market Share by Type (2017-2028)
    Figure 13. United States Bi-Specific Antibodies Therapy Market Share by Type in 2022 & 2028
    Figure 14. United States Bi-Specific Antibodies Therapy Market Size by Type (2017-2028) & (US$ Million)
    Figure 15. United States Bi-Specific Antibodies Therapy Market Share by Type (2017-2028)
    Figure 16. Product Picture of Cancer
    Figure 17. Product Picture of Haemophilia
    Figure 18. Product Picture of Other Non-Cancer Diseases
    Figure 19. Global Bi-Specific Antibodies Therapy Market Share by Application in 2022 & 2028
    Figure 20. Global Bi-Specific Antibodies Therapy Market Size by Application (2017-2028) & (US$ Million)
    Figure 21. Global Bi-Specific Antibodies Therapy Market Share by Application (2017-2028)
    Figure 22. United States Bi-Specific Antibodies Therapy Market Share by Application in 2022 & 2028
    Figure 23. United States Bi-Specific Antibodies Therapy Market Size by Application (2017-2028) & (US$ Million)
    Figure 24. United States Bi-Specific Antibodies Therapy Market Share by Application (2017-2028)
    Figure 25. North America Bi-Specific Antibodies Therapy Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 26. United States Bi-Specific Antibodies Therapy Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 27. Canada Bi-Specific Antibodies Therapy Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 28. Europe Bi-Specific Antibodies Therapy Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 29. Germany Bi-Specific Antibodies Therapy Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 30. France Bi-Specific Antibodies Therapy Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 31. U.K. Bi-Specific Antibodies Therapy Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 32. Italy Bi-Specific Antibodies Therapy Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 33. Russia Bi-Specific Antibodies Therapy Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 34. Asia-Pacific Bi-Specific Antibodies Therapy Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 35. China Bi-Specific Antibodies Therapy Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 36. Japan Bi-Specific Antibodies Therapy Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 37. South Korea Bi-Specific Antibodies Therapy Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 38. India Bi-Specific Antibodies Therapy Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 39. Australia Bi-Specific Antibodies Therapy Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 40. China Taiwan Bi-Specific Antibodies Therapy Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 41. Indonesia Bi-Specific Antibodies Therapy Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 42. Thailand Bi-Specific Antibodies Therapy Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 43. Malaysia Bi-Specific Antibodies Therapy Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 44. Latin America Bi-Specific Antibodies Therapy Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 45. Mexico Bi-Specific Antibodies Therapy Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 46. Brazil Bi-Specific Antibodies Therapy Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 47. Argentina Bi-Specific Antibodies Therapy Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 48. Middle East & Africa Bi-Specific Antibodies Therapy Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 49. Turkey Bi-Specific Antibodies Therapy Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 50. Saudi Arabia Bi-Specific Antibodies Therapy Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 51. UAE Bi-Specific Antibodies Therapy Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 52. Roche Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2017-2022)
    Figure 53. Amgen Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2017-2022)
    Figure 54. Sanofi Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2017-2022)
    Figure 55. Pfizer Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2017-2022)
    Figure 56. Johnson & Johnson Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2017-2022)
    Figure 57. AstraZeneca Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2017-2022)
    Figure 58. AbbVie Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2017-2022)
    Figure 59. Lindis Biotech Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2017-2022)
    Figure 60. MacroGenics, Inc Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2017-2022)
    Figure 61. Genmab Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2017-2022)
    Figure 62. Alphamab Co. Ltd Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2017-2022)
    Figure 63. Akeso, Inc. Revenue Growth Rate in Bi-Specific Antibodies Therapy Business (2017-2022)
    Figure 64. Bottom-up and Top-down Approaches for This Report
    Figure 65. Data Triangulation
    Figure 66. Key Executives Interviewed

A bispecific antibody (BsAb), or specific monoclonal antibody (BsMAb) is an artificial protein comprised of fragments from two different antibodies. By virtue of the inclusion of two different antigen binding regions, a bispecific antibody is capable of recognizing and binding to two different antigens, or two different epitope on an antigen.

Market Analysis and Insights: Global and United States Bi-Specific Antibodies Therapy Market
This report focuses on global and United States Bi-Specific Antibodies Therapy market, also covers the segmentation data of other regions in regional level and county level.

Due to the COVID-19 pandemic, the global Bi-Specific Antibodies Therapy market size is estimated to be worth US$ 4201.5 million in 2022 and is forecast to a readjusted size of US$ 17140 million by 2028 with a CAGR of 26.4% during the review period. Fully considering the economic change by this health crisis, by Type, Fragment-Based Antibodies accounting for % of the Bi-Specific Antibodies Therapy global market in 2021, is projected to value US$  million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While by Application, Cancer was the leading segment, accounting for over  percent market share in 2021, and altered to an  % CAGR throughout this forecast period.

Global Bi-Specific Antibodies Therapy key players include Roche, Amgen, Sanofi, Pfizer, Johnson & Johnson, etc. Global top five manufacturers hold a share over 95%.

North America is the largest market, with a share about 65%, followed by Europe and China, both have a share over 30 percent. In terms of product, IgG-Based Antibodies is the largest segment, with a share over 85%. And in terms of application, the largest application is Haemophilia, followed by Cancer, etc.

Global Bi-Specific Antibodies Therapy Scope and Market Size
Bi-Specific Antibodies Therapy market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Bi-Specific Antibodies Therapy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.

For United States market, this report focuses on the Bi-Specific Antibodies Therapy market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.

Segment by Type, the Bi-Specific Antibodies Therapy market is segmented into
    Fragment-Based Antibodies
    IgG-Based Antibodies

Segment by Application, the Bi-Specific Antibodies Therapy market is segmented into
    Cancer
    Haemophilia
    Other Non-Cancer Diseases

Regional and Country-level Analysis
    North America
        United States
        Canada
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
    Asia-Pacific
        China
        Japan
        South Korea
        India
        Australia
        China Taiwan
        Indonesia
        Thailand
        Malaysia
    Latin America
        Mexico
        Brazil
        Argentina
    Middle East & Africa
        Turkey
        Saudi Arabia
        UAE

Competitive Landscape and Bi-Specific Antibodies Therapy Market Share Analysis
Bi-Specific Antibodies Therapy market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2017-2022. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2017-2022. Details included are company description, major business, company total revenue and the sales, revenue generated in Bi-Specific Antibodies Therapy business, the date to enter into the Bi-Specific Antibodies Therapy market, Revenue in Bi-Specific Antibodies Therapy Business (2017-2022) & (US$ Million) introduction, recent developments, etc.

The major vendors covered:
    Roche
    Amgen
    Sanofi
    Pfizer
    Johnson & Johnson
    AstraZeneca
    AbbVie
    Lindis Biotech
    MacroGenics, Inc
    Genmab
    Alphamab Co. Ltd
    Akeso, Inc.